Tiansheng Pharmaceutical Group Co Ltd

ST Tian Sheng released its 2026 interim report on August 25, 2026. The company's total operating revenue was 233 million yuan, net profit attributable to the parent company was a loss of 24.1731 million yuan, and net cash inflow from operating activities was 44.3636 million yuan. The company's latest asset-liability ratio was 24.69%, gross margin was 48.84%, a decrease of 0.05 percentage points from the same period last year, latest ROE was negative 1.25%, and diluted earnings per share was negative 0.08 yuan. The company's latest total asset turnover was 0.09 times, inventory turnover was 1.21 times, number of shareholders was 10,300, and the top ten shareholders held 149 million shares, accounting for 46.91% of total share capital.

ST Tian Sheng released its 2026 interim report. Operating revenue was 233 million yuan, up 0.3 percent year on year. Net profit attributable to the parent swung from a loss of 36.71 million yuan in the same period last year to a loss of 24.17 million yuan, narrowing the deficit. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 40.93 million yuan a year earlier to a loss of 27.24 million yuan, also narrowing the deficit. Net operating cash flow was 44.36 million yuan, up 74.9 percent year on year. In the second quarter, operating revenue was 101 million yuan, down 13.4 percent year on year. Net profit attributable to the parent swung from a loss of 24.3 million yuan in the same period last year to a loss of 14.39 million yuan, narrowing the deficit. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 27.23 million yuan a year earlier to a loss of 15.18 million yuan, also narrowing the deficit. As of the end of the second quarter, total assets stood at 2.569 billion yuan, down 2.9 percent from the end of the previous year. Net assets attributable to the parent were 1.927 billion yuan, down 1.2 percent from the end of the previous year. In the interim report, the company said its overall operations face multiple risks and challenges, including medical insurance cost controls, centralized drug procurement and stricter industry regulation, and it will continue to focus on innovation-driven development and compliant operations.

The Chongqing Bureau of the China Securities Regulatory Commission has imposed a penalty on Beijing Xinghua Certified Public Accountants for failing to perform its duties diligently during the audit of Tian Sheng Pharmaceutical's 2017 annual report. Investigations found that Tian Sheng Pharmaceutical's 2017 annual report overstated total profit by approximately 92.2 million yuan, accounting for 30.21 percent of the disclosed total profit for the period, while Xinghua issued a standard unqualified audit report. The Chongqing Bureau ordered Xinghua to rectify the issue, confiscated business income of about 1.18 million yuan, and imposed a fine of approximately 2.36 million yuan, bringing the total penalty to around 3.54 million yuan. The signing certified public accountants Ye Min and Li Jie were each given a warning and fined 50,000 yuan.